
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and preliminary overall survival results for IDE849 (SHR-4…
IDYA is down 5.27% today. Volume is 1.19M vs a 30-day average of 881.9K (1.35x).
IDEAYA Biosciences, Inc. is scheduled to report earnings Mon, Nov 2, 2026. Analysts expect EPS of $-1.21 on revenue of about $6.99M. Stocks often move sharply on earnings day.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and preliminary overall survival results for IDE849 (SHR-4…

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in…
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced updated clinical data from three ongoing studies evaluating darovasertib in …
William Blair analyst Alethia Young initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform rating.